Full Breakdown
President Trump's Eli Lilly Stock Purchases Overlap Federal GLP-1 Initiatives
5/18/2026, 9:01:12 PM
Core Event: Stock Purchases Coincide with GLP-1 Policy Timeline
Ethics disclosures released May 14 list seven Eli Lilly stock purchases by President Donald Trump between Jan 6 and Mar 31, 2024. The first buy preceded the Jan 8 CMS deadline for a Medicare GLP-1 pilot; a Feb 10 purchase of West Pharmaceutical Services followed. On May 15, Trump’s son Eric said any family-directed trading is “a lie and blatantly false.”
Background & Context: Federal Moves Favoring GLP-1 Drugs
The White House launched TrumpRx, a portal directing patients to low-cost GLP-1 drugs such as Lilly’s Zepbound and to LillyDirect. The FDA intensified a February crackdown on compounded GLP-1s and, in April, approved Lilly’s Foundayo pill via a priority-voucher. CMS’s BALANCE pilot, proposing $50-monthly Medicare coverage for GLP-1s, lists Lilly as a participant and targets Medicare and Medicaid beneficiaries to improve health outcomes.
Official Statements & Responses
The Trump Organization said an independent broker handles the investments and denied family direction; Eric Trump called the claim “a lie.” HHS declined comment, referring to the White House, which pointed to the Trump Organization. Lilly described its inclusion in the CMS pilot as a significant milestone. FDA Commissioner Marty Makary praised the rapid Foundayo approval. The White House referred questions to the Trump Organization.
Criticism & Opposition
Legal ethicist Kathleen Clark warned that a president buying stock in a company affected by his administration “undermines the public’s trust in two ways,” emphasizing the need to separate personal gain from public duty. Ethics scholars say the mere appearance of a conflict can erode confidence. A congressional ban on presidential trading would require legislation.
Conflicting Reports & Gaps
Four of the seven Lilly purchases are labeled “unsolicited,” a term the Office of Government Ethics has not explained. The disclosures do not show whether Trump directed any trades. Both Lilly and HHS have offered no comment on the timing.
Verbatim Quotes
- “To suggest that individual stocks are being bought or sold, at the discretion of any member of the Trump family, would be a lie and blatantly false.” — Eric Trump, Trump Organization executive
- “A president who buys or sells the stock of a company whose value is affected by his administration’s actions undermines the public’s trust in two ways,” — Kathleen Clark, legal ethicist, Washington University in St. Louis
- “This approval demonstrates what the FDA can achieve when we eliminate delays and prioritize fast and thorough work from the agency and industry partners,” — Marty Makary, former FDA Commissioner
- “significant milestone.” — Eli Lilly statement on CMS GLP-1 pilot participation
What’s Next: Legislative and Policy Outlook
Congressional bills to prohibit presidential stock trading remain under consideration. The CMS BALANCE pilot is slated to transition to permanent Medicare coverage by mid-2026, a change analysts say could further lift Lilly’s revenue and market valuation.
